Apr 20, 2010 - Link demonstrated between elesclomol anti-cancer activity and levels of HIF-1a and LDH - Additional results presented demonstrating activity of elesclomol in cisplatin-resistant lung cancer models - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced preclinical results presented at the American Association for Cancer Research (AACR) 101st Annual Meeting that support correlative markers for elesclomol anti-cancer activity. In addition, results were presented by Synta collaborators showing that elesclomol demonstrates activity in cisplatin-resistant lung cancer models... Synta Pharmaceuticals' Press Release -
Apr 21, 2010
Synta Pharmaceuticals : Results at AACR Supporting Correlative Markers for Elesclomol Activity
Apr 20, 2010 - Link demonstrated between elesclomol anti-cancer activity and levels of HIF-1a and LDH - Additional results presented demonstrating activity of elesclomol in cisplatin-resistant lung cancer models - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced preclinical results presented at the American Association for Cancer Research (AACR) 101st Annual Meeting that support correlative markers for elesclomol anti-cancer activity. In addition, results were presented by Synta collaborators showing that elesclomol demonstrates activity in cisplatin-resistant lung cancer models... Synta Pharmaceuticals' Press Release -
